On November 21, 2016, the U.S. Court of Appeals for the First Circuit upheld a 2014 jury verdict for AstraZeneca (AZ) and Ranbaxy regarding a 2012 payment of $700 million from AstraZeneca for Ranbaxy to abandon its challenge...more
12/5/2016
/ Antitrust Violations ,
Appeals ,
Generic Drugs ,
Hatch-Waxman ,
Jury Verdicts ,
Pay-For-Delay ,
Pharmaceutical Patents ,
Popular ,
Reverse Payment Settlement Agreements ,
Rule-of-Reason Analysis ,
Summary Judgment